Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain langauage summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Faculty of 1000 evaluation for A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers., August 2013, Faculty of 1000, Ltd., DOI: 10.3410/f.717955710.793481436.
You can read the full text:

Open access logo


Be the first to contribute to this page